Last Saturday marked International Women’s Day, a time to reflect on the progress we’ve made towards gender equity and, just as importantly, the work still ahead.

Our Health Insights product has been featured in The Times. Our test is described as “the first genetic test capable of accurately predicting the risk of common diseases in an attempt to improve prevention”. Bupa will be the first Genomics customer to offer the service in the UK, after a pilot with 300 people.

Genomics has been recognised as a Top Drug Discovery and Development Solutions Provider 2025 by Pharma Tech Outlook.

GENOMICS has always had a strong sense of culture and community - you can feel it the moment you walk through the door. I felt it on my first day, and it’s a big part of why people join and why they stay. But until now, we’ve never taken the time to put into words what truly makes us us.

Our CEO and Founder, Professor Sir Peter Donnelly, was interviewed on BBC News regarding the UK Government's plans for investment in the Oxford and Cambridge region.

Genomics has been recognised in the Sunday Times 100 Tech 2025, as one of Britain’s fastest growing private tech companies. The prestigious ranking was published this morning on The Times website. The list ranks Britain’s private tech companies on growth in annual revenues, measured over three years. There are two tables which make up the 100 Tech: the top 50 software, and the top 50 hardware companies. We ranked 41 in the hardware category.

The Times covered our latest work in preventing obesity using genetics, and the highlights from the keynote speech given by our CEO and Founder Professor Sir Peter Donnelly at the Bupa Healthcare Symposium: Unboxing Digital Health2024. More than half of adults across the world are overweight or suffering from obesity according to the World Health Organisation, but genomic sequencing and a proactive, personalised and preventative approach to treatment could help to solve the global obesity crisis.

The Financial Times covered our latest ground-breaking research, showing that gene screening can cut early disease deaths by 25%. A simple genetic screening test has the potential to stop almost a quarter of premature preventable deaths from common diseases including breast cancer, diabetes and hypertension, by identifying those most at risk.